Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
5.64 USD +0.98% Intraday chart for electroCore, Inc. -5.84% -5.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ElectroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness CI
ElectroCore, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : ElectroCore, Inc., Q4 2023 Earnings Call, Mar 13, 2024
ElectroCore, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (ECOR) ELECTROCORE Posts Q4 Revenue $5.2M, vs. Street Est of $5M MT
Certain Common Stock of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024. CI
Certain Warrants of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024. CI
Certain Options of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024. CI
HC Wainwright Adjusts electroCore Price Target to $15 From $11, Maintains Buy Rating MT
Ondine Biomedical appoints Joseph Errico as new CFO AN
ElectroCore Says Two US Patents Issued for Non-Invasive Vagus Nerve Stimulation Technology MT
ElectroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board CI
Transcript : ElectroCore, Inc. - Analyst/Investor Day
HC Wainwright Adjusts Price Target on electroCore to $11 From $10, Maintains Buy Rating MT
Transcript : ElectroCore, Inc., Q3 2023 Earnings Call, Nov 08, 2023
ElectroCore, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (ECOR) ELECTROCORE Posts Q3 Revenue $4.5M, vs. Street Est of $3.8M MT
Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation for Treatment of Symptoms of Gastroparesis CI
ElectroCore, Inc. Announces Two-Year Extension of Gammacore Device Listing in the NHS Supply Chain Catalogue CI
ElectroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder CI
ElectroCore Wins Dismissal of Lawsuit Over 2018 Initial Public Offering MT
Transcript : ElectroCore, Inc., Q2 2023 Earnings Call, Aug 09, 2023
ElectroCore, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (ECOR) ELECTROCORE Reports Q2 Revenue $3.6M, vs. Street Est of $3.5M MT
ElectroCore, Inc. Reiterates Revenue Guidance for the Year 2023 CI
Chart electroCore, Inc.
More charts
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Company’s TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.64 USD
Average target price
23.1 USD
Spread / Average Target
+309.57%
Consensus
  1. Stock Market
  2. Equities
  3. ECOR Stock
  4. News electroCore, Inc.
  5. ElectroCore : Wins New US Patent for Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices